

Proteus Syndrome - Pipeline Insight, 2019

<https://marketpublishers.com/r/P233C54871EEN.html>

Date: August 2019

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: P233C54871EEN

Abstracts

This report can be delivered to the clients within 24 Hours

"Proteus Syndrome - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Proteus Syndrome pipeline landscape is provided which includes the disease overview and Proteus Syndrome treatment guidelines. The assessment part of the report embraces, in depth Proteus Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Proteus Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Proteus Syndrome Understanding

"Proteus syndrome also known as (Wiedemann syndrome; Elephant Man's disease) is a rare condition characterized by overgrowth of the bones, skin, and other tissues. Organs and tissues affected by the disease grow out of proportion to the rest of the body. The overgrowth is usually asymmetric, which means it affects the right and left sides of the body differently. Newborns with Proteus syndrome have few or no signs of the condition. Overgrowth becomes apparent between the ages of 6 and 18 months and gets more severe with age. In people with Proteus syndrome, the pattern of overgrowth varies greatly but can affect almost any part of the body. Bones in the limbs, skull, and spine are often affected. The condition can also cause a variety of skin growths, particularly a thick, raised, and deeply grooved lesion known as a cerebriiform connective tissue nevus. This type of skin growth usually occurs on the soles of the feet and is hardly ever seen in conditions other than Proteus syndrome. Blood vessels (vascular tissue) and fat (adipose tissue) can also grow abnormally in Proteus

syndrome.

Proteus Syndrome Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Proteus Syndrome targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Proteus Syndrome pipeline report covers only one company. The only key player include ArQule (Miransertib) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Proteus Syndrome Analytical Perspective by DelveInsight

In-depth Proteus Syndrome Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Proteus Syndrome Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

The Proteus Syndrome report provides an overview of therapeutic pipeline activity for Proteus Syndrome across the complete product development cycle

including all clinical and non-clinical stages

It comprises of detailed profiles of Proteus Syndrome therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Proteus Syndrome Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Proteus Syndrome

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Proteus Syndrome to formulate effective R&D strategies

Assess challenges and opportunities that influence Proteus Syndrome R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially

lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Get in detail information of each product with updated information on each project along with key milestones

Devise Proteus Syndrome in licensing and out licensing strategies by identifying prospective partners with progressing projects for Proteus Syndrome to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in

decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Contents

1. REPORT INTRODUCTION

2. PROTEUS SYNDROME (WIEDEMANN SYNDROME) (ELEPHANT MAN'S DISEASE)

2.1. Proteus Syndrome Disease Overview

2.2. Proteus Syndrome History

2.3. Proteus Syndrome Symptoms

2.4. Proteus Syndrome Causes

2.5. Proteus Syndrome Pathophysiology

2.6. Proteus Syndrome Diagnosis

2.6.1. Diagnostic Guidelines

3. PROTEUS SYNDROME CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. PROTEUS SYNDROME - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment

4.1.1. Proteus Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Proteus Syndrome Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Proteus Syndrome Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono / Combination)

4.2.2.1. Assessment by Stage and Product Type

4.2.3. Assessment by Route of Administration

4.2.3.1. Assessment by Stage and Route of Administration

4.2.4. Assessment by Molecule Type

4.2.4.1. Assessment by Stage and Molecule Type

4.2.5. Assessment by MOA

4.2.5.1. Assessment by Stage and MOA

5. PROTEUS SYNDROME PIPELINE THERAPEUTICS

- 5.1. Late Stage Products (Phase-III)
 - 5.1.1. Comparative Analysis
- 5.2. Mid Stage Products (Phase-II)
 - 5.2.1. Comparative Analysis
- 5.3. Early Stage Products (Phase-I)
 - 5.3.1. Comparative Analysis
- 5.4. Pre-clinical and Discovery Stage Products
 - 5.4.1. Comparative Analysis
- 5.5. Inactive Products

6. PROTEUS SYNDROME -PRODUCTS ANALYSIS

- 6.1. Product Profiles
 - 6.1.1. Miransertib- ArQule
 - 6.1.1.1. Product Description
 - 6.1.1.1.1. Product Overview
 - 6.1.1.1.2. Mechanism of Action
 - 6.1.1.2. Research and Development
 - 6.1.1.2.1. Clinical Studies
 - 6.1.1.2.1.1. Detailed Study Description
 - 6.1.1.2.1.2. Study Results
 - 6.1.1.2.1.3. Clinical Trials: Tabular View
 - 6.1.1.3. Product Development Activities
 - 6.1.1.3.1. Tabulated Product Summary
 - 6.1.1.3.1.1. General Description Table
 - 6.1.1.4. Product Development Activities
 - 6.1.1.4.1. Tabulated Product Summary
 - 6.1.1.4.1.1. General Description Table
- To be continued in the report.....

7. RECENT TECHNOLOGIES

8. PROTEUS SYNDROME KEY COMPANIES

- 8.1. ArQule

9. PROTEUS SYNDROME KEY PRODUCTS

9.1. Miransertib

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. PROTEUS SYNDROME - UNMET NEEDS

12. PROTEUS SYNDROME - FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research

14.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

- Table 1. Proteus Syndrome Diagnostic Guidelines
- Table 2. Treatment Guidelines
- Table 3. Assessment Summary
- Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5. Proteus Syndrome Acquisition Analysis
- Table 6. Assessment by Phase of Development
- Table 7. Assessment by Product Type (Mono / Combination)
- Table 8. Assessment by Stage and Product Type
- Table 9. Assessment by Route of Administration
- Table 10. Assessment by Stage and Route of Administration
- Table 11. Assessment by Molecule Type
- Table 12. Assessment by Stage and Molecule Type
- Table 13. Assessment by MOA
- Table 14. Assessment by Stage and MOA
- Table 15. Late Stage Products (Phase-III)
- Table 16. Mid Stage Products (Phase-II)
- Table 17. Early Stage Products (Phase-I)
- Table 18. Pre-clinical and Discovery Stage Products
- Table 19. Inactive Products
- Table 20. Dormant Products
- Table 21. Discontinued Products

List Of Figures

LIST OF FIGURES

- Figure 1. Disease Overview
- Figure 2. History
- Figure 3. Symptoms
- Figure 4. Causes
- Figure 5. Pathophysiology
- Figure 6. Diagnostic Guidelines
- Figure 7. Treatment Guidelines
- Figure 8. Proteus Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
- Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
- Figure 10. Proteus Syndrome Acquisition Analysis
- Figure 11. Assessment by Phase of Development
- Figure 12. Assessment by Product Type (Mono / Combination)
- Figure 13. Assessment by Stage and Product Type
- Figure 14. Assessment by Route of Administration
- Figure 15. Assessment by Stage and Route of Administration
- Figure 16. Assessment by Molecule Type
- Figure 17. Assessment by Stage and Molecule Type
- Figure 18. Assessment by MOA
- Figure 19. Assessment by Stage and MOA
- Figure 20. Late Stage Products (Phase-III)
- Figure 21. Mid Stage Products (Phase-II)
- Figure 22. Early Stage Products (Phase-I)
- Figure 23. Pre-clinical and Discovery Stage Products
- Figure 24. Inactive Products
- Figure 25. Dormant Products
- Figure 26. Discontinued Products
- Figure 27. Unmet Needs

KEY COMPANIES

ArQule

I would like to order

Product name: Proteus Syndrome - Pipeline Insight, 2019

Product link: <https://marketpublishers.com/r/P233C54871EEN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P233C54871EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970